IcoSema significantly lowers postprandial glucose increments compared to other insulin regimens in adults with T2D

Type 2 Diabetes (T2D) is characterized by impaired insulin and incretin responses, leading to elevated postprandial glucose (PPG) levels after meals and subsequent postprandial hyperglycemia. Current standard-of-care insulin regimens often struggle to optimally control these post-meal glucose spikes, which are a significant contributor to overall glycemic burden and long-term complications. This research investigates whether IcoSema, a novel once-weekly combination of basal insulin icodec and semaglutide, offers superior PPG control compared to other established insulin-based therapies, addressing a critical gap in T2D management.

This post hoc analysis utilized continuous glucose monitoring (CGM) data from the randomized, phase 3a COMBINE 1 and 3 trials to evaluate IcoSema's effect on PPG control. The study compared IcoSema (once-weekly basal insulin icodec + semaglutide) against once-weekly basal insulin icodec (COMBINE 1) or daily basal-bolus therapy (BBT; insulin glargine U100 + insulin aspart; COMBINE 3). CGM data collected during weeks 48-52 were analyzed using a modified Glucose Rate Increase Detector (GRID) algorithm to estimate mealtimes and derive PPG endpoints. The primary aim was to determine IcoSema's effect on PPG control in adults with inadequately controlled T2D.

Data from 1650 participants were analyzed, revealing an average of 2.3 meals/day/participant detected across both trials. IcoSema treatment consistently demonstrated superior postprandial glucose control compared to both icodec and daily basal-bolus therapy. The key findings revolved around significant reductions in post-meal glucose excursions. Specifically, IcoSema treatment resulted in statistically significantly lower mean peak PPG increment values. This indicates a blunted and more controlled glucose response immediately following meals. Furthermore, IcoSema also led to statistically significantly lower 90-min PPG increment and 120-min PPG increment values, suggesting sustained improvement in glucose handling over a longer postprandial period. The abstract also noted a faster time to return to normal glucose levels, though the specific metrics were truncated. These results highlight IcoSema's dual action, combining basal insulin's foundational control with semaglutide's incretin-mediated effects, to effectively mitigate post-meal hyperglycemia. The consistent statistical significance across multiple PPG metrics underscores the robustness of these findings.

IcoSema treatment resulted in statistically significantly lower mean peak PPG increment, 90-min PPG increment, and 120-min PPG increment values.